This trial is a proof-of-concept, pilot study, phase I/II clinical trial aimed at generating preliminary data on the combination of golcadomide, poseltinib, and rituximab.
Subjects must satisfy the following criteria to be enrolled in the study
Subject is ≥ 19 years of age at the time of signing the informed consent form (CRF).
Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
Subject who has had prior treatment with golcadomide.
Subject who has had prior treatment with BTK inhibitor.
Subject has life expectancy ≤ 2 months.
Subject has previously received solid organ transplantation.